Abstract

Objective: To assess the frequency of hepatitis-c reinfection after treatment with direct-acting antiviral (DAA) therapy undergoing maintenance hemodialysis.
Methodology: This observational, cross-sectional study included 160 patients in the Department of Nephrology, JPMC, from November 2019 to October 2020. The sampling technique used was non-probability. Demographic information, such as age, gender, HCV genotype, HCV RNA, and comorbidities, was gathered from the medical data or by interviews with patients and family members.
Results: The severity of liver disease was classified according to the Child-Turcotte-Pugh (CTP) score. We found that 38.9% patients had an average score of 6, and 53.7% were classified in CTP class A. The re-infection rate of HCV was very low after treatment with DAA.
Conclusion: DAAs have become a successful treatment for HCV, allowing the virus to be eradicated.

Key words: Reinfection, hepatitis c, Sofosbuvir, hemodialysis, virological response.